Ceasing to be a substantial holder
Released
Released
Announcement PDF
Form 605
Corporations Act 2001
Section 671 B
Notice of ceasing to be a substantial holder
To Company Name/Scheme
Mayne Pharma Group Limited
ACN/ARSN
ACN 115 832 963
1.
Details of substantial holder (1)
Name
Mithra Pharmaceuticals SA, Estetra SRL and their associates listed in Annexure A
ACN/ARSN (if applicable)
NIA
The holder ceased to be a substantial holder
on
The previous notice was given to the
company on
The previous notice was dated
2.
21 June 2023
14 May 2021
14 May 2021
Changes in relevant interests·
Particulars of each change in, or change in the nature of, a relevant interest (2) of the substantial holder or 'an associate (3) in voting
securities of the company or scheme, since the substantial holder was last required to give a substantial holding notice to the company
or scheme are as follows:
Date of
change
Person whose
relevant interest
changed
Nature of
change (4)
Consideration given in
relation to change (5)
Class (6) and number
of securities affected
Person's votes
affected
21/6/2023
Mithra
Pharmaceuticals SA,
Estetra SRL and their
associates listed in
Annexure A
On-market sale
$16,296,206
4,221,815 fully paid
ordinary shares
4,221,815 fully
paid ordinary
shares
3.
Changes in association
The persons who have become associates (3) of, ceased to be associates of, or have changed the nature of their association (7) with,
the substantial holder in relation to voting interests in the company or scheme are as follows:
Name and ACN/ARSN (if
applicable)
Nature of association
Refer to Annexure A
The associates listed in Annexure A are members of the same group of
companies as Mithra Pharmaceuticals SA and Estetra SRL.
4
Addresses
The addresses of persons named in this form are as follows:
Address
Rue Saint-Georges 5, 4000 Liége, Belgium
Name
Estetra SRL
Mithra Pharmaceuticals SA
Rue Saint-Georges 5, 4000 Liége, Belgium
Associates listed in Annexure A
Refer to Aimexure A
2499-VI\AUS_LPL\AD9
Signature
print name
CHR$ToPH
1
1ARCHAL caaci
date !nue 2023
Directions
1.
If there are a number of substantial holders with similar or related relevant interests (eg. a corporation and its related
corporations, or the manager and trustee of an equity trust), the names could be included in an annexure to the form. If the
relevant interests of a group of persons are essentially similar, they may be referred to throughout the form as a specifically
named group if the membership of each group, with the names and addresses of members is clearly set out in paragraph 4 of
the form.
2.
See the definition of"relevant interest" in sections 608 and 671B(7) of the Corporations Act 2001.
3.
See the definition of "associate" in section 9 of the Corporations Act 2001.
4.
Include details of:
(a)
any relevant agreement or other circumstances because of which the change in relevant interest occurred.
If
subsection 6718(4) applies, a copy of any document setting out the terms of any relevant agreement, and a statement
by the person giving full and accurate details of any contract, scheme or arrangement, must accompany this form,
together with a written statement certifying this contract, scheme or arrangement; and
(b)
any qualification of the power of a person to exercise, control the exercise of, or influence the exercise of, the voting
powers or disposal of the securities to which the relevant interest relates (indicating clearly the particular securities to
which the qualification applies).
5.
Details of the consideration must include any and all benefits, money and other, that any person from whom a relevant
interest was acquired has, or may, become entitled to receive in relation to that acquisition. Details must be included even if
the benefit is conditional on the happening or not of a contingency. Details must be included of any benefit paid on behalf of
the substantial holder or its associate in relation to the acquisitions, even if they are not paid directly to the person from
whom the relevant interest was acquired.
6.
The voting shares of the company constitute one class unless divided into separate classes.
7.
Give details, if appropriate, of the present association and any change in that association since the last substantial holding
notice.
2499-vl\AUS_LPL\AD9
Annexure A
This is Annexure A referred to in Form 605 (Notice of ceasing to be a substantial holder), signed by me and dated
7
Signature:
tAAgc A
Name:
Title:
d$1.±
ZZ June 2023.
C
q#fi..
1
Associates
The following is a list of associates of Mithra Pharmaceuticals SA and Estetra SRL.
Name of Associate
Address
Mithra Recherche et Développement SA
Rue Saint-Georges 5, 4000 Liége, Belgium
Neuralis SA
Rue Saint-Georges 5, 4000 Liége, Belgium
Mithra Létzebuerg SA
Boulevarddela Petrusse 124, 2330 Luxembourg
Mithra Pharmaceuticals COMO SA
Rue Saint-Georges 5, 4000 Liége, Belgium
Mithra Pharmaceuticals GmbH
Promenade 3-9 Raumm 22 DE - 52076 Aachen, Germany
WeCare Pharmaceuticals BV
Lagedijk 1-3, NL - 1541 KA Koog aan de Zaan
Novalon SA
Rue Saint-Georges 5, 4000 Liége, Belgium
Donesta Bioscience BV
Boslaan 11 3701 CH Zeist, The Netherlands
2499-v I \AUS_LPLIAD9
Share your feedback
Discover